Opinion
Whether they’re newly minted managers or C-suite executives, effective managers often lead with empathy, intellectual curiosity and vulnerability.
Longeveron and Lexeo Therapeutics are working on CGT therapies to treat Alzheimer’s disease, but it’s not clear whether they have a better chance of success than traditional approaches.
The advantages of using circular RNAs—including increased durability, enhanced protein expression and substantially lower manufacturing costs compared to linear mRNAs—have driven a spate of investment in this technology.
Restructuring can invite lawsuits if companies aren’t careful. Following local, state and federal rules is critical, as is keeping the employee handbook current.
Why I advocated on Capitol Hill this month for the renewal of the FDA’s Priority Review Voucher program
Artificial intelligence is making it faster to get drug candidates to the clinic, but to gain a competitive advantage, companies must have a strong foundation of data.
It’s important to maintain anonymity when seeking your next executive role, as your departure could impact other employees and the organization.
Continuing investment in basic infectious disease research and pandemic preparedness infrastructure isn’t just about being ready for the next pandemic—it’s also a smart business move.
Shifts in the FDA’s approach present an unprecedented opportunity to solve problems with patient access and trial design.
Plus, what to do if your offer is paused and how to manage work anxiety.